[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Anelli A, Lima CA, Younes RN, Gross JL, Fogarolli R: Chemotherapy versus best supportive care in stage IV non-small cell lung cancer, non metastatic to the brain. Rev Hosp Clin Fac Med Sao Paulo; 2001 Mar-Apr;56(2):53-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy versus best supportive care in stage IV non-small cell lung cancer, non metastatic to the brain.
  • Stage IV non-small cell lung cancer is a fatal disease, with a median survival of 14 months.
  • Systemic chemotherapy is the most common approach.
  • OBJECTIVES: To determine differences in overall survival and quality of life among patients with stage IV non-small cell lung cancer non-metastatic to the brain treated with best supportive care versus systemic chemotherapy.
  • PATIENTS: From February 1990 through December 1995, 78 eligible patients were admitted with the diagnosis of stage IV non-small cell lung cancer.
  • Patients were divided in 2 groups: Group A (n=31 - treated with best supportive care ), and Group B (n=47 - treated with systemic chemotherapy).
  • RESULTS: The median survival time was 23 weeks (range 5 - 153 weeks) in Group A and 55 weeks (range 7.4 - 213 weeks) in Group B (p=0.0018).
  • Patients receiving systemic chemotherapy were also stratified into those receiving mytomycin, vinblastin, and cisplatinum, n=25 and those receiving other combination regimens (platinum derivatives associated with other drugs, n=22).
  • Patients receiving mytomycin, vinblastin, and cisplatinum, n=25 had a higher incidence of febrile neutropenia and had their cycles delayed for longer periods of time than the other group.
  • These patients also had a shorter median survival time (51 versus 66 weeks, p=0.005).
  • CONCLUSION: In patients with stage IV non-small cell lung cancer, non-metastatic to the brain, chemotherapy significantly increases survival compared with best supportive care.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy. Palliative Care / methods


2. Kosmas C, Tsavaris NB, Makatsoris T, Onyenadum A, Vadiaka M, Stavroyianni N, Sepsas E, Dimitropoulos D, Rokana S, Kalofonos HP: A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer. Int J Cancer; 2002 Mar 1;98(1):141-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
  • In an attempt to develop more effective chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC), we evaluated docetaxel-ifosfamide-cisplatin (DIP) based on our previous experience with paclitaxel-ifosfamide-cisplatin.
  • Patients with advanced NSCLC (stages III-IV), WHO-PS< or =2, no prior chemotherapy and unimpaired hematopoietic and organ function were eligible.
  • Chemotherapy was administered in successive dose levels (DLs) and included docetaxel (80-100 mg/m2 day 1), ifosfamide (4-5 g/m2) and cisplatin (80-100 mg/m2), both divided over days 1 and 2 every 21 days.
  • Fifty-five patients were accrued (phase I: 15; phase II: 40) and all are evaluable for response and toxicity: median age = 58 (40-72); PS = 1 (0-2); gender = 48 males, 7 females; stages IIIA = 8, IIIB = 19, IV = 28; and histologies were adenocarcinoma (29), squamous (20), large cell (6).
  • Metastatic sites at diagnosis included lymph nodes (33), bone (8), liver (6), brain (6), lung nodules (9), adrenals (7) and soft tissue (1).
  • The median response duration was 7 months (2-21+), median time to progression (TTP) 8 months (1-23+) and median overall survival (OS) 13 months (2-23+).
  • Randomized comparisons to current standard 2-drug regimens will be warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11857398.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


3. Lau CP, Leung WK: Caecal metastasis from a primary small-cell lung carcinoma. Hong Kong Med J; 2008 Apr;14(2):152-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caecal metastasis from a primary small-cell lung carcinoma.
  • Small bowel metastases from a primary lung carcinoma are rare.
  • We report a case of a 59-year-old male with a primary small-cell lung carcinoma who developed anaemia and bowel symptoms.
  • On colonoscopic examination he was found to have a tumour in the caecum near the ileocaecal valve, which was biopsied, revealing small neuroendocrine tumour cells.
  • The patient then underwent systemic chemotherapy, which achieved a reduction in the size of the primary lung tumour and an improvement in his bowel symptoms.
  • It is important that such a rare condition be recognised early as complicated intestinal metastases from a lung carcinoma can lead to high mortality rates and poor short-term outcome.
  • With advances in chemotherapy and palliative care, patients with metastatic lung carcinoma can sometimes survive more than a year with reasonable quality of life.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382025.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


Advertisement
4. Boutemy M, Mispelaere D, Krzisch C, Jounieaux V: [Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma]. Rev Mal Respir; 2005 Jun;22(3):413-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma].
  • [Transliterated title] Evaluation de la chimiothérapie associant vinorelbine-ifosfamide-cisplatine dans le traitement des cancers bronchiques non à petites cellules métastatiques.
  • Non small cell lung cancer (NSCLC) represents 80% of bronchial carcinoma of which 40-50% are mefastatic at the time of diagnosis.
  • At present, although the therapeutic benefits are modest, it is now recognised that combination chemotherapy including platinum salts improves the survival of these patients.
  • METHODS: We analysed retrospectively a cohort of 57 patients suffering from stage IV NSCLC treated with chemotherapy combining cisplatin (80 mg/rn2 on day 1), vinorelbine (25 mg/rn2 on days 1 and 8) and ifosfamide (3000 mg/in 2 on day 1), (NIP), repeated every 21 days.
  • All patients were studied in terms of toxicity and overall survival but only 40 (70%) were able to be evaluated in terms of response to treatment (on account of having received more than three cycles of NIP chemotherapy).
  • For the 40 patients for whom chemotherapy was evaluable, the objective response rate was 20%.
  • CONCLUSION: Treatment of stage IV NSCLC with NIP chemotherapy is effective and improves the survival of these patients independently of other prognostic factors such as age, the presence of cerebral metastases, performance status, histological type, the number of metastatic sites or the serum LOH level.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Bronchogenic / drug therapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cohort Studies. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Life Tables. Male. Middle Aged. Retrospective Studies. Smoking / adverse effects. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227927.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


5. Kong DS, Lee JI, Nam DH, Park K, Kim JH, Kim JG, Park JO, Park K: Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery. J Korean Med Sci; 2006 Jun;21(3):527-32
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery.
  • The clinical outcome and prognostic factors of patients with synchronous brain metastases from non-small cell lung cancer (NSCLC) who were treated with gamma knife radiosurgery (GKS) were analyzed.
  • A total of 35 patients with NSCLC underwent GKS as an initial treatment for metastatic brain lesions of synchronous onset.
  • The period of survival and various prognostic factors such as age, gender, performance status, multiplicity of the brain lesions, intracranial tumor volume, and extent of the primary tumor were analyzed.
  • The overall median survival time for this series was 12 months (range 0.75 to 43 months) from the diagnosis.
  • Multivariate analysis of these data revealed that N stage, whole-brain radiotherapy (WBRT), and chemotherapy were significant predictors for survival (p<0.05).
  • Survival of patients with NSCLC and synchronous brain metastases is mainly dependent upon the progression of the systemic disease, provided that the cerebral lesions are treated adequately with local treatment modalities including radiosurgery.
  • Application of radiosurgery as an initial treatment option and aggressive local and systemic modalities to control extracranial disease may improve survival.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Time Factors. Treatment Outcome


6. Olson JJ, Paleologos NA, Gaspar LE, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Patchell RA, Ryken TC, Kalkanis SN: The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol; 2010 Jan;96(1):115-42
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.
  • QUESTION: What evidence is available regarding the emerging and investigational therapies for the treatment of metastatic brain tumors?
  • TARGET POPULATION: These recommendations apply to adults with brain metastases.
  • RECOMMENDATIONS: New radiation sensitizers Level 2 A subgroup analysis of a large prospective randomized controlled trial (RCT) suggested a prolongation of time to neurological progression with the early use of motexafin-gadolinium (MGd).
  • Interstitial modalities There is no evidence to support the routine use of new or existing interstitial radiation, interstitial chemotherapy and or other interstitial modalities outside of approved clinical trials.
  • New chemotherapeutic agents Level 2 Treatment of melanoma brain metastases with whole brain radiation therapy and temozolomide is reasonable based on one class II study.
  • Level 3 Depending on individual circumstances there may be patients who benefit from the use of temozolomide or fotemustine in the therapy of their brain metastases.
  • Molecular targeted agents Level 3 The use of epidermal growth factor receptor inhibitors may be of use in the management of brain metastases from non-small cell lung carcinoma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Combined Modality Therapy / methods. Practice Guidelines as Topic
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Cranial Irradiation / methods. Disease Progression. Evidence-Based Medicine. Humans. Metalloporphyrins / therapeutic use. Radiation-Sensitizing Agents / therapeutic use. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2006 Oct;17(10):1592-7 [17005632.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1883-90 [16986123.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):44-8 [17146474.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):306-12 [17149755.001]
  • [Cites] BMC Cancer. 2007;7:18 [17254350.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3637-41 [17575228.001]
  • [Cites] Onkologie. 2007 Jul;30(7):361-6 [17596744.001]
  • [Cites] Neurosurg Focus. 2007;22(3):E3 [17608356.001]
  • [Cites] Lung Cancer. 2007 Sep;57(3):359-64 [17434236.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):277S-289S [17873174.001]
  • [Cites] Am J Clin Oncol. 2007 Dec;30(6):580-7 [18091051.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):85-90 [17987262.001]
  • [Cites] J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S113-8 [18520292.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3351-7 [18612151.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1069-76 [18977094.001]
  • [Cites] J Neurooncol. 2010 Jan;96(1):11-6 [19957012.001]
  • [Cites] Melanoma Res. 2003 Feb;13(1):97-103 [12569292.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2364-71 [12805339.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2529-36 [12829672.001]
  • [Cites] Phys Ther. 2003 Aug;83(8):713-21 [12882612.001]
  • [Cites] J Neurooncol. 1999 Jun;43(2):173-8 [10533730.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):53-7 [10582669.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4959-67 [10987313.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2074-83 [11283141.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):249-54 [11300333.001]
  • [Cites] Jpn J Clin Oncol. 2001 Jun;31(6):251-8 [11463802.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):259-65 [11718258.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Apr;128(4):214-8 [11935312.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3445-53 [12177105.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3644-50 [12202665.001]
  • [Cites] Oncology. 2002;63(4):333-7 [12417787.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):157-65 [14701778.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2101-7 [15169796.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1042-7 [15205197.001]
  • [Cites] Melanoma Res. 2004 Aug;14(4):289-94 [15305160.001]
  • [Cites] Lung Cancer. 2004 Nov;46(2):255-61 [15474674.001]
  • [Cites] Clin Lung Cancer. 2004 Sep;6(2):123-8 [15476598.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(4):263-6 [2403853.001]
  • [Cites] Med Dosim. 1990 Dec;15(4):217-9 [2073335.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1993;58:112-4 [8109271.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):711-7 [8040016.001]
  • [Cites] Eur J Cancer. 1994;30A(14):2093-5 [7857710.001]
  • [Cites] Acta Neurochir (Wien). 1994;131(1-2):91-6 [7709790.001]
  • [Cites] Can J Neurol Sci. 1995 Feb;22(1):13-6 [7750066.001]
  • [Cites] Acta Neurochir Suppl. 1995;63:29-34 [7502724.001]
  • [Cites] Br J Neurosurg. 1995;9(5):593-603 [8561931.001]
  • [Cites] Eur J Cancer. 1996 Jan;32A(1):69-71 [8695244.001]
  • [Cites] Melanoma Res. 1996 Oct;6(5):399-401 [8908601.001]
  • [Cites] J Neurooncol. 1997 Jul;33(3):213-21 [9195493.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):129-38 [15603863.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):185-91 [15629610.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):61-5 [15719277.001]
  • [Cites] Neoplasma. 2005;52(2):150-8 [15800714.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):950-7 [15829494.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2590-7 [15861414.001]
  • [Cites] Lung Cancer. 2005 Nov;50(2):247-54 [16039010.001]
  • [Cites] J Neurosurg. 2005 Oct;103(4):630-5 [16266044.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(1):34-9 [16010592.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):106-14 [16314619.001]
  • [Cites] J Neurooncol. 2006 Jan;76(1):59-64 [16132502.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1023-30 [16446056.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):137-44 [16510849.001]
  • [Cites] Clin Transl Oncol. 2006 Apr;8(4):266-70 [16648102.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1777-84 [16773073.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):277-80 [16614943.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3):375-84 [16961129.001]
  • [Cites] Ann Oncol. 2006 Sep;17(9):1412-7 [16790516.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1348-54 [16909414.001]
  • (PMID = 19957013.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metalloporphyrins; 0 / Radiation-Sensitizing Agents; 6433A42F4F / motexafin gadolinium
  • [Other-IDs] NLM/ PMC2808529
  •  go-up   go-down


7. Fujimoto S, Yamaguchi Y, Gotanda H, Shiozawa R, Takemura A, Umeda-Kameyama Y, Yamamoto H, Iijima K, Akishita M, Ouchi Y: [A case of limbic encephalitis with small cell lung carcinoma in which the cognitive function improved and redeteriorated during tumor therapy]. Nihon Ronen Igakkai Zasshi; 2010;47(1):79-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of limbic encephalitis with small cell lung carcinoma in which the cognitive function improved and redeteriorated during tumor therapy].
  • The brain CT and EEG showed no specific abnormalities and an analysis of cerebrospinal fluid showed only a mild increase in the total protein level.
  • A chest X-ray film revealed a mass in the right hilum, while a histological analysis of the biopsied specimen finally established a diagnosis of small cell lung carcinoma.
  • The FDG-PET and the enhanced brain MRI showed a single small metastatic lesion in the cerebellum.
  • After the 1st course of chemotherapy and whole brain radiation, cognitive function, especially the short-term memory, remarkably improved and the HDS-R score increased to 21/30.
  • However, the tumor again increased in size during the 3(rd) and 4(th) courses of chemotherapy.
  • Interestingly, cognitive function also worsened again and the score of HDS-R declined to 15/30, 20 weeks after the start of chemotherapy.
  • Limbic encephalitis can be associated with malignant tumors, such as small cell lung carcinoma, and some reported cases have shown a cognitive improvement after tumor therapy.
  • [MeSH-major] Cognition Disorders / etiology. Limbic Encephalitis / complications. Lung Neoplasms / complications. Lung Neoplasms / therapy. Small Cell Lung Carcinoma / complications. Small Cell Lung Carcinoma / therapy

  • Genetic Alliance. consumer health - Limbic encephalitis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339211.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Koide N, Hiraguri M, Kishimoto K, Nakamura T, Adachi W, Miyabayashi H, Terai N, Amano J: Small cell carcinoma of the esophagus with reference to alternating multiagent chemotherapy: report of two cases. Surg Today; 2003;33(4):294-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the esophagus with reference to alternating multiagent chemotherapy: report of two cases.
  • We herein report the findings of two patients with small cell carcinoma of the esophagus (SCEC) who were treated with alternating chemotherapy using cisplatin and etoposide (PVP), and cyclophosphamide, adriamycin or epirubicin, and vincristine (CAV).
  • The patient underwent an esophagectomy following PVP/CAV-therapy.
  • Six months later her serum level of Pro-GRP became elevated, and multiple metastases to the liver and lung were detected.
  • Two courses of PVP/CAV-therapy were performed, and these metastatic foci almost completely disappeared.
  • One year after surgery, multiple brain metastases and recurrence of liver metastases were detected, then the serum level of Pro-GRP became re-elevated.
  • Two courses of PVP/CEV-therapy were performed, and the metastases to the brain and liver decreased in size.
  • However, the brain metastases relapsed, and the patient died 21 months after the diagnosis.
  • Patient 2 was treated with two courses of preoperative PVP/CAV-therapy; however, the patient died of multiple liver metastases 17 months after the diagnosis.
  • In six previously documented patients and the two present patients who were treated with PVP/CAV-therapy, the primary or metastatic foci of SCEC decreased in size, and the mean survival of the patients was 19 months.
  • In conclusion, PVP/CAV alternating chemotherapy is beneficial for prolonging the survival of SCEC patients; however, new chemotherapeutic modalities are still needed to further improve the prognosis of SCEC patients.
  • Furthermore, the level of serum Pro-GRP in patients with SCEC may be both a diagnostic marker and a therapeutic monitor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Peptide Fragments / blood. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12707827.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Fujita A, Fukuoka S, Takabatake H, Tagaki S, Sekine K: Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology; 2000 Nov;59(4):291-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer.
  • BACKGROUND: Brain metastases develop frequently in patients with non-small cell lung cancer (NSCLC), and the prognosis for these patients is very poor.
  • We evaluated the role of chemotherapy for patients with brain metastases from NSCLC.
  • METHODS: We analyzed 30 patients who were discovered to have brain metastases during the diagnosis of 121 patients enrolled in three consecutive clinical trials on advanced NSCLC assessing combination chemotherapy of cisplatin, ifosfamide and irinotecan with rhG-CSF support.
  • Response in the brain lesions was evaluated by contrast-enhanced MRI scans after at least two courses.
  • The response rate in brain metastases was 50.0%, and that in extracranial primary and metastatic lesions was 62.1%.
  • After completing chemotherapy, Gamma Knife radiosurgery was performed on 2 patients in remission and 8 patients at disease progression.
  • The median survival time and 1-year survival rate were 382 days and 56.1%, respectively.
  • CONCLUSIONS: Both the response rate and survival data in this retrospective study suggest a high degree of activity of this combination chemotherapy in patients with brain metastases from NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Camptothecin / analogs & derivatives. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / secondary. Granulocyte Colony-Stimulating Factor / therapeutic use. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Radiosurgery. Radiotherapy, Adjuvant. Recombinant Proteins. Retrospective Studies. Survival Analysis. Treatment Outcome


10. Erhan Y, Dikmen Y, Yucebilgin MS, Zekioglu O, Mgoyi L, Terek MC: Large cell neuroendocrine carcinoma of the uterine corpus metastatic to brain and lung: case report and review of the literature. Eur J Gynaecol Oncol; 2004;25(1):109-12
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the uterine corpus metastatic to brain and lung: case report and review of the literature.
  • Neuroendocrine carcinoma of the uterine corpus is a rare aggressive tumor with a similar unfavorable outcome to that of the cervix.
  • The large cell type is considerably rarer than the small cell neuroendocrine carcinoma of the uterine corpus.
  • We report a case of a 52-year-old woman who presented with a large cell neuroendocrine tumor of the uterine corpus with very aggressive clinical behavior, cerebral and pulmonary metastases six and four months after initial diagnosis and adjuvant radiotherapy, respectively.
  • Despite successful surgical extirpation of the cerebral metastatic lesion she did not respond to chemotherapy and died four months after disease recurrence.
  • [MeSH-major] Brain Neoplasms / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Lung Neoplasms / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15053077.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 31
  •  go-up   go-down


11. Louie AV, Rodrigues G, Yaremko B, Yu E, Dar AR, Dingle B, Vincent M, Sanatani M, Younus J, Malthaner R, Inculet R: Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin Lung Cancer; 2009 May;10(3):174-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer.
  • BACKGROUND: Reports in the medical literature have described cases of extended survival of patients with non-small-cell lung cancer (NSCLC) with solitary metastatic disease who have received aggressive treatment both to the brain metastasis and to the local/regional disease.
  • PATIENTS AND METHODS: A single-institution, retrospective chart review was performed on 35 patients with NSCLC and a synchronous solitary brain metastasis (SSBM) treated with craniotomy and whole-brain radiation therapy.
  • Eight patients (22.9%) had chest surgery, 24 (68.6%) had chemotherapy, and 14 (40%) had thoracic radiation as part of their local management.
  • Mean age at diagnosis was 58.5 years.
  • Eighteen patients (56.25%) had a brain metastasis < 3 cm, and 14 patients (43.75%) had a metastasis > 3 cm.
  • Univariate analysis demonstrated that lung surgery (P = .0033), primary lung treatment > 8 weeks after brain surgery (P = .0128), and stage I/II disease (P = .0467) were predictive of overall survival.
  • However, patients with thoracic disease amenable to local resection should be considered for such therapy because a survival advantage could exist compared with patients with more locally advanced disease.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


12. Hall WA, Djalilian HR, Nussbaum ES, Cho KH: Long-term survival with metastatic cancer to the brain. Med Oncol; 2000 Nov;17(4):279-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival with metastatic cancer to the brain.
  • Metastatic cancer to the brain has a poor prognosis.
  • The focus of this work was to determine the incidence of long-term (> or = 2y) survival for patients with brain metastases from different primary cancers and to identify prognostic variables associated with prolonged survival.
  • A retrospective review of 740 patients with brain metastases treated over a 20 y period identified 51 that survived 2 or more years from the time of diagnosis of the brain metastasis.
  • Prognostic variables that were examined included age, sex, histology, tumor number and location, and treatment.
  • For all tumor types (740 patients), the actuarial survival rate was 8.1% at 2 y, 4.8% at 3 y, and 2.4% at 5 y.
  • At 2 y, patients with ovarian carcinoma had the highest survival rate (23.9%) and patients with small cell lung cancer (SCLC) had the lowest survival rate (1.7%).
  • At 5y, survival rates were 7.8% for ovarian carcinoma, 2.9% for non-SCLC, 2.3% for melanoma and renal cell carcinoma, 1.3% for breast carcinoma and there were no survivors with SCLC, gastrointestinal, bladder, unknown primary, or prostate cancer.
  • Age, sex, histology, location for single tumors, systemic chemotherapy, and stereotactic radiosurgery did not significantly influence survival.
  • Multivariate analysis showed younger age (P< 0.05), single metastasis (P < 0.0001), surgical resection (P < 0.0001), whole brain radiation therapy (P < 0.0001), and chemotherapy (P = 0.0288) were associated with prolonged survival.
  • Patients with a single non-SCLC, breast, melanoma, renal cell, and ovarian carcinoma brain metastasis have the best chance for long-term survival if treated with surgical resection and WBRT.
  • [MeSH-major] Brain Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Renal Cell / pathology. Combined Modality Therapy. Female. Humans. Kidney Neoplasms / pathology. Lung Neoplasms / pathology. Male. Melanoma / pathology. Middle Aged. Ovarian Neoplasms / pathology. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Survivors

  • Genetic Alliance. consumer health - Brain Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1993 Feb;11(2):369-73 [8426215.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):605-16 [7674008.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):300-4 [1648994.001]
  • [Cites] J Neurooncol. 1993 Feb;15(2):165-74 [8509821.001]
  • [Cites] Neurol Clin. 1995 Nov;13(4):915-25 [8584004.001]
  • [Cites] Arch Neurol. 1978 Nov;35(11):754-6 [718475.001]
  • [Cites] Chest. 1992 May;101(5):1293-7 [1316262.001]
  • [Cites] Strahlenther Onkol. 1995 May;171(5):290-5 [7770785.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):87-90 [8455067.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2340-4 [7964950.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):27-35 [8641923.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1366-70 [3017537.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1085-92 [8648361.001]
  • [Cites] Surg Neurol. 1991 Dec;36(6):458-61 [1759186.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1781-8 [8859192.001]
  • [Cites] J Neurosurg. 1993 Aug;79(2):210-6 [8331402.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):459-84 [8823775.001]
  • [Cites] Ann Neurol. 1993 Jun;33(6):583-90 [8498838.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):447-57 [8823774.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Surg Neurol. 1993 Mar;39(3):230-4 [8456388.001]
  • (PMID = 11114706.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Edelman MJ, Khanwani SL: Advanced non-small cell lung cancer. Curr Treat Options Oncol; 2001 Feb;2(1):51-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced non-small cell lung cancer.
  • The treatment of advanced non-small cell lung cancer requires histologic proof of diagnosis, careful staging, and assessment of each patient's performance status and comorbidities.
  • For patients with stage IIIB (pleural effusion) and stage IV disease who have a Cancer and Leukemia Group B performance status (PS) of 0 to 1, appropriate management consists of combination chemotherapy with a platinum (either cisplatin or carboplatin) combined with paclitaxel, gemcitabine, vinorelbine, docetaxel, or CPT-11.
  • For patients who maintain a good performance status after first-line chemotherapy, second-line treatment may be considered.
  • Current evidence supports the use of docetaxel as second-line treatment if the patient has not previously received this drug.
  • Vinorelbine, ifosfamide, and CPT-11 appear to be inactive as second-line therapy for patients who have previously received platinum-based chemotherapy.
  • For patients with a PS of 2, single-agent chemotherapy with vinorelbine, gemcitabine, or a combination of the two should be considered.
  • Patients with poor performance status should be treated with supportive measures designed to relieve pain and acute complications because any tumor-directed therapy has limited benefit.
  • Special situations exist in which curative therapy for metastatic disease is a possibility.
  • Patients who present with solitary sites of metastatic disease, particularly after a long disease-free interval and in the CNS may undergo definitive surgery or radiotherapy with curative intent.
  • Surgical treatment or definitive radiotherapy should not be employed unless a thorough restaging evaluation is performed that includes computed tomography scan of the chest and abdomen through adrenals, brain magnetic resonance imaging, and positron emission tomography scan.
  • A plethora of new agents targeting angiogenesis, tumor invasiveness, the hypoxic environment of tumors, and the cell cycle are currently in development.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Patient Selection. Salvage Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1990;27(3):243-7 [2176134.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1408-16 [9537241.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):799-805 [10997806.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2459-65 [9667264.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):623-31 [10653877.001]
  • [Cites] Oncology (Williston Park). 1998 Feb;12(2):199-209; discussion 210, 215-6 pass [9507521.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):116-26 [9428487.001]
  • [Cites] Med Pediatr Oncol. 1990;18(3):197-202 [2158614.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2081-5 [10561261.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):376-87 [10699068.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3188-94 [10506617.001]
  • [Cites] Lung Cancer. 1998 May;20(2):85-91 [9711526.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1301-9 [2166142.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1602-13 [2553879.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2354-62 [10856094.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2996-3018 [9256144.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1036-44 [9849452.001]
  • [Cites] Ann Thorac Surg. 1995 Dec;60(6):1609-11 [8787451.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1462-6 [1649268.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3 Suppl 11):13-8 [10458205.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1351-9 [10715308.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1353-8 [10717616.001]
  • [Cites] Am J Clin Oncol. 1998 Feb;21(1):67-71 [9499262.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3816-21 [10577854.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):66-72 [9890172.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):122-30 [10623702.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1556-62 [2167953.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1451-7 [10735892.001]
  • [Cites] Anticancer Drugs. 1995 Feb;6(1):3-18 [7538829.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2529-36 [10893283.001]
  • (PMID = 12057140.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


14. Irifune K, Hamada H, Yokoyama A, Kondo K, Kohno N, Hara Y, Hiwada K: [A case of central diabetes insipidus caused by metastatic small cell lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2002 Feb;40(2):154-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of central diabetes insipidus caused by metastatic small cell lung cancer].
  • Chest CT films showed mediastinal lymphadenopathy, nodules in the lung fields, and pleural effusion.
  • Histopathologic examination of transbronchial biopsy specimens showed oat cell carcinoma.
  • Central diabetes insipidus caused by pituitary metastasis of small cell lung cancer was diagnosed.
  • After treatment with whole-brain irradiation and chemotherapy, the size of the swollen pituitary stalk was reduced and his urine volume decreased.
  • He died of respiratory insufficiency 15 months after the initial diagnosis.
  • This was a rare case of central diabetes insipidus caused by pituitary metastasis of small cell lung cancer successfully treated with radiotherapy and chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell / complications. Diabetes Insipidus / etiology. Lung Neoplasms / complications


15. Abe T, Hayashi M, Tsutsui N, Ito K, Haraguchi M: [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2006 Feb;44(2):144-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].
  • "Case 1" A 56-year-old woman who suffered from postoperative recurrent non-small cell lung cancer received gefitinib therapy.
  • Approximately 7 months after the therapy was begun, although the intrathoracic disease responded to the treatment, she developed meningeal carcinomatosis and died of rapidly progressive central nervous system disease.
  • "Case 2" A 46-year-old man with stage IV non-small cell lung cancer started gefitinib therapy after chemotherapy.
  • The pulmonary lesions markedly improved responding to gefitinib therapy, however, approximately 6 months after the therapy was begun, multiple brain metastasis and meningeal carcinomatosis were detected.
  • Approximately 4 months after the diagnosis of meningeal carcinomatosis, he died of disease progression and disturbance of consciousness.
  • It has been reported that the central nervous system is a frequent metastatic site of non-small cell lung cancer in patients treated with gefitinib.
  • We report two cases of meningeal carcinomatosis that occurred during the period in which their intrathoracic disease was responding to gefitinib therapy.
  • We should consider the possibility of metastatic central nervous system disease, even in patients in whom gefitinib therapy is apparently successful.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / etiology. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Meningeal Neoplasms / etiology. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Disease Progression. Fatal Outcome. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228810.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


16. Lüdike A, Knolle J, Schön R, Hinze P, Hofmann HS, Schreiber J: [Primary pulmonary rhabdomyosarcoma as a rare differential diagnosis of small cell lung cancer]. Pneumologie; 2005 Jul;59(7):456-60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary pulmonary rhabdomyosarcoma as a rare differential diagnosis of small cell lung cancer].
  • Primary pulmonary rhabdomyosarcoma is a rare entity and the histological differential diagnosis can be difficult.
  • We report on a 43-year old female patient, smoker (25 pack-years), in whom a large solitary brain metastasis was diagnosed and enucleated.
  • Histological examination revealed a typical small cell carcinoma and histological examination of biopsies obtained from a tumor in the left upper lobe of the lung was compatible with a small cell carcinoma.
  • Despite chemotherapy there was a progressive tumor growth.
  • Bronchial biopsies again showed a small cell tumor, although immunohistochemistry proved it to be a pleomorphic rhabdomyosarcoma.
  • Due to the progressive tumor growth with necrosis and superinfection and a lack of further metastases lobectomy of the left upper lobe was performed, complicated by postoperative pleural empyema, limiting the possibilities of adjuvant therapy.
  • Laminectomy and extirpation of the spinal metastases, local radiotherapy and chemotherapy with iphosphamide and doxorubicine led to partial remission and clinical improvement for few months only.
  • The patient died from metastatic primary rhabdomyosarcoma of the lung.
  • This rare tumor mimicked small cell lung cancer.
  • Appraisal of the atypical clinical course and a close dialogue between pathologists and clinicians enabled the correct diagnosis.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Lung Neoplasms / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Recurrence

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16047279.001).
  • [ISSN] 0934-8387
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Jesien-Lewandowicz E, Spych M, Fijuth J, Kordek R: Solitary brain metastasis of an occult and stable small-cell lung cancer in a schizophrenic patient: a 3-year control. Lung Cancer; 2010 Aug;69(2):245-8
Hazardous Substances Data Bank. CLOZAPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary brain metastasis of an occult and stable small-cell lung cancer in a schizophrenic patient: a 3-year control.
  • Small-cell lung cancer is a highly aggressive carcinoma, with poorer prognosis in patients with brain metastases.
  • We present the case of a 49-year-old woman diagnosed with a cerebellar tumour which, following surgery, was revealed to be a metastatic small-cell lung carcinoma.
  • Subsequent CT and PET scanning showed a small, isolated 8 mm nodule in the upper lobe of the right lung.
  • Because of the unusual presentation, there was no therapy given for the primary tumour at the time, and systemic therapy or surgery was discussed.
  • On pathology examination, the tumour was presented as a typical small-cell carcinoma.
  • Standard chest irradiation with systemic chemotherapy was given.
  • At the time of writing, 39 months after diagnosis of metastatic small-cell carcinoma, the patient is disease free.
  • However, this case is unusual in that a long-term observation of a small stable primary tumour in the lung took place without any therapy being given.
  • This case strongly supports the thesis that small-cell lung cancer may comprise a heterogeneous group of tumours with different biological properties.
  • [MeSH-major] Brain Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Schizophrenia / diagnosis. Small Cell Lung Carcinoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antipsychotic Agents / therapeutic use. Carboplatin / administration & dosage. Clozapine / therapeutic use. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Middle Aged. Radiotherapy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20537425.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; J60AR2IKIC / Clozapine
  •  go-up   go-down


18. Kosmas C, Tsavaris N, Koutras A, Makatsoris T, Mylonakis N, Tzelepis G, Dimitrakopoulos A, Spyropoulos K, Polyzos A, Karabelis A, Kalofonos HP: A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer. Oncology; 2005;69(4):333-41
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
  • PURPOSE: In the present phase II study we evaluated the docetaxel-ifosfamide-carboplatin (DICb) combination in the outpatient setting in patients with advanced non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Patients with advanced NSCLC (stages IIIB/IV), WHO performance status (PS) <2, and no prior chemotherapy were eligible.
  • Chemotherapy drug doses were: docetaxel: 80 mg/m2, ifosfamide: 3.5 g/m2, and carboplatin at a target area under the curve of 5 (based on Calvert's formula), all on day 1, followed by prophylactic G-CSF.
  • Metastatic sites at diagnosis included: lymph nodes: 25; bone: 7; liver: 4; brain: 5; lung nodules: 13; adrenals: 6.
  • The median response duration was 7 months (range 2-14 months), median time to progression 9 months (range 2-18 months) and median overall survival 11 months (range 3-46+ months).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Actuarial Analysis. Aged. Carboplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Neoplasm Staging. Quality of Life. Survival Analysis. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16282711.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


19. Shirai S, Sukoh N, Yamamoto H, Suzuki I, Kamimura A, Yoshida K, Suzuki A, Inoue M, Watanabe N: [A case of small cell lung cancer with paraneoplastic cerebellar degeneration and anti-voltage-gated calcium channel antibody]. Nihon Kokyuki Gakkai Zasshi; 2001 Jan;39(1):40-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of small cell lung cancer with paraneoplastic cerebellar degeneration and anti-voltage-gated calcium channel antibody].
  • Chest X-ray films revealed a mass shadow in the right upper lobe of the lung, and transbronchial brushing specimens showed small-cell carcinoma.
  • Extensive examination revealed metastatic lesions in the mediastinal lymph nodes and liver, but brain MRI showed no findings suggestive of metastasis or atrophy.
  • A diagnosis of PCD associated with SCLC was made, and the patient had a high titer of anti-P/Q-type VGCC antibody.
  • He was treated by chemotherapy and radiation therapy, which resulted in a transient improvement in the PCD symptoms.
  • [MeSH-major] Autoantibodies / analysis. Calcium Channels, N-Type / immunology. Carcinoma, Small Cell / diagnosis. Lung Neoplasms / diagnosis. Paraneoplastic Cerebellar Degeneration / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Cerebellar Degeneration.
  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Paraneoplastic cerebellar degeneration.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11296385.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Calcium Channels, N-Type; 0 / voltage-dependent calcium channel (P-Q type)
  •  go-up   go-down


20. Kosmas C, Tsavaris NB, Polyzos A, Kalofonos HP, Sepsas E, Malamos NA, Vadiaka M, Dosios T, Antonopoulos MJ: A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma. Cancer; 2000 Aug 15;89(4):774-82
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
  • BACKGROUND: The necessity to develop more effective chemotherapy regimens in advanced nonsmall cell lung carcinoma (NSCLC) prompted the authors to evaluate the paclitaxel-ifosfamide-cisplatin (PIC) combination, developed on the basis of high individual single-agent activity, in vitro synergism, and tolerance as determined in a previous Phase I study by the authors.
  • PATIENTS: Eligibility criteria included advanced NSCLC (American Joint Committee on Cancer [AJCC]/International Union Against Cancer [UICC] Stage III/IV), Eastern Cooperative Oncology Group performance status (PS) </= 2, no prior chemotherapy, and unimpaired hematopoietic and organ function.
  • Chemotherapy included, paclitaxel 175 (in the first 10 patients) or 200 mg/m(2) on Day 1, ifosfamide: 5 g/m(2) divided over Days 1 and 2, and cisplatin 100 mg/m(2) divided over Days 1 and 2, recycled every 21 days.
  • Metastatic sites at diagnosis included lymph nodes, 33 patients; bone, 6; liver, 5; brain, 10; lung nodules, 7; adrenals, 6; other, 2.
  • The median response duration was 7 months (range 2-34+); median time-to-progression, 8 months (range, 1-36+), median overall survival, 12 months (range, 2-36+).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Patient Compliance. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10951340.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


21. Gugger M, Kappeler A, Vonlanthen S, Altermatt HJ, Ris HB, Lardinois D, Borner MM, Heighway J, Betticher DC: Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours. Lung Cancer; 2001 Aug-Sep;33(2-3):229-39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours.
  • Prognosis of lung cancer is related to stage of disease at time of diagnosis.
  • In this study we examine alterations of pathways governing the cell cycle, in particular pRb-cyclinD1-p16 alpha and p53-p14ARF, in a series of NSCLC (n=92) at different stages at diagnosis.
  • In 12 patients, metastatic sites (5 lymph node, 3 bone, 2 brain and 2 gastrointestinal metastases) were available for comparison with the primary tumour: 19 altered protein expressions were found to be concordant, six additional alterations (in 4 patients) were found in the metastases only, especially in lymph node metastases (3 patients).
  • No protein studied had a predictive significance for response after chemotherapy in non-resectable tumours.
  • These results demonstrate a strong correlation between stage and pathway alterations, cell cycle regulators being less likely altered in advanced NSCLC.
  • This finding might be an explanation for distinct biological behaviour (e.g. chemotherapy response) of resectable versus advanced disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Cell Cycle Proteins / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Aged. Cell Cycle. Cell Nucleus / metabolism. Cyclin D1 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Cyclin-Dependent Kinase Inhibitor p21. Cyclins / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Proteins / metabolism. Retinoblastoma Protein / metabolism. Survival Rate. Tumor Suppressor Protein p14ARF. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11551418.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Proteins; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


22. Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M: Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol; 2009 Jun;55(6):1293-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).
  • BACKGROUND: Recent publications suggest a benefit from surgical removal of urothelial carcinoma metastases (UCM) for a subgroup of patients.
  • INTERVENTION: Resected metastatic sites were the following: retroperitoneal lymph nodes (56.8%), distant lymph nodes (11.3%), lung (18.2%), bone (4.5%), adrenal gland (2.3%), brain (2.3%), small intestine (2.3%), and skin (2.3%).
  • Systemic chemotherapy was administered in 35 of 44 patients (79.5%) before and/or after UCM surgery.
  • MEASUREMENTS: Overall, cancer-specific and progression-free survival from time of diagnosis and metastasectomy of UCM.
  • RESULTS AND LIMITATIONS: Median survival from initial diagnosis of UCM and subsequent resection was as follows: overall survival, 35 mo and 27 mo; cancer-specific survival, 38 mo and 34 mo; and progression-free survival, 19 mo and 15 mo.
  • Metastasectomy in patients with disseminated UCM remains investigational and should only be offered to those with limited disease as a combined-modality approach with systemic chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / surgery. Lymph Node Excision / methods. Urologic Neoplasms / pathology. Urologic Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Female. Germany. Humans. Kaplan-Meier Estimate. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Jun;55(6):1300-1 [19124189.001]
  • (PMID = 19058907.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Serizawa T, Iuchi T, Ono J, Saeki N, Osato K, Odaki M, Ushikubo O, Hirai S, Sato M, Matsuda S: Gamma knife treatment for multiple metastatic brain tumors compared with whole-brain radiation therapy. J Neurosurg; 2000 Dec;93 Suppl 3:32-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife treatment for multiple metastatic brain tumors compared with whole-brain radiation therapy.
  • OBJECT: The purpose of this retrospective study was to compare the effectiveness of gamma knife radiosurgery (GKS) for multiple cerebral metastases with that of whole-brain radiation therapy (WBRT).
  • METHODS: Ninety-six consecutive patients with cerebral metastases from nonsmall cell lung cancer were treated between 1990 and 1999.
  • The entry criteria were the presence of between one and 10 multiple brain lesions at initial diagnosis, no surgically inaccessible tumors with more than a 30-mm diameter, no carcinomatous meningitis, and more than 2 months of life expectancy.
  • In the GKS group, large lesions (> 30 mm) were removed surgically and all other small lesions (< or = 30 mm) were treated by GKS.
  • In the WBRT group, the patients were treated by the traditional combined therapy of WBRT and surgery.
  • In both groups, chemotherapy was administered according to the primary physician's protocol.
  • The two groups did not differ in terms of age, sex, initial Karnofsky Performance Scale (KPS) score, type, lesion number, and size of lesion, systemic control, and chemotherapy.
  • CONCLUSIONS: Gamma knife radiosurgery without prophylactic WBRT could be a primary choice of treatment for patients with as many as 10 cerebral metastases from nonsmall cell cancer.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Cranial Irradiation. Lung Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11143259.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Mommens V, Bosquée L, D'Orio V: [Clinical case of the month. Pulmonary toxicity due to gemcitabine for NSCLC with brain metastasis]. Rev Med Liege; 2003 Mar;58(3):123-6
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical case of the month. Pulmonary toxicity due to gemcitabine for NSCLC with brain metastasis].
  • Gemcitabine pulmonary toxicity is rare and represents a difficult diagnosis.
  • A 61 year old female treated with gemcitabine for a metastatic non-small cell lung cancer (NSCLC) developed during the fifth chemotherapy cycle an acute respiratory distress syndrome with fever, tachypnea, marked hypoxemia and a diffuse interstitial-alveolar infiltrate on chest radiograph.
  • This acute pneumonitis was likely drug induced.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Lung Diseases / chemically induced. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12723505.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases
  •  go-up   go-down


25. Read RW, Green RL, Rao NA: Metastatic adenocarcinoma with rupture through the Bruch membrane simulating a choroidal melanoma. Am J Ophthalmol; 2001 Dec;132(6):943-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma with rupture through the Bruch membrane simulating a choroidal melanoma.
  • PURPOSE: To report a case of adenocarcinoma metastatic to the choroid with rupture through the Bruch membrane, thus, simulating a choroidal melanoma.
  • Further examination revealed a left, upper lobe, nonsmall cell lung carcinoma.
  • CONCLUSION: Metastatic choroidal tumors may present, although rarely, with collar-button configurations.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / pathology. Bruch Membrane / pathology. Choroid Neoplasms / secondary. Melanoma / diagnosis. Retinal Detachment / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Diagnosis, Differential. Eye Enucleation. Female. Fluorescein Angiography. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Middle Aged. Pain / diagnosis. Rupture, Spontaneous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11730672.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Gillani JA, Iqbal M, Nasreen S, Khan A, Samad A: Unilateral blindness as a presenting symptom of lung cancer treated with erlotinib. J Coll Physicians Surg Pak; 2008 Feb;18(2):125-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral blindness as a presenting symptom of lung cancer treated with erlotinib.
  • Clinical work-up revealed metastatic deposits in left retina.
  • Broadened workup also showed metastatic disease in the skull and brain.
  • The search for the primary concluded on the histopathological evidence of Non-Small Cell Lung Carcinoma (NSCLC) in the upper lobe of the left lung.
  • After the diagnosis and ascertaining disease extent, localized radiotherapy to whole skull and retina was given, followed by conventional chemotherapy (Gemcitabine, Carboplatin).
  • The results of radiation and chemotherapy were not satisfactory, therefore, patient was placed on a new agent (tyrosine kinase inhibitor) Erlotinib (150 mg per day orally in a single dose).
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Carboplatin / adverse effects. Carcinoma, Non-Small-Cell Lung / complications. Deoxycytidine / analogs & derivatives. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols. Erlotinib Hydrochloride. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454905.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


27. Peacock KH, Lesser GJ: Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol; 2006 Nov;7(6):479-89
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic approaches in patients with brain metastases.
  • The development of brain metastases is often viewed as the end stage of a disease course and engenders skepticism about the efficacy of treatment.
  • Aggressive management of brain metastases is effective in both symptom palliation and the prolongation of life.
  • Single brain metastases should be treated with surgical resection or stereotactic radiosurgery, though it is unclear at this time if one modality is more effective than the other.
  • Surgical resection is preferred when a pathologic diagnosis is needed, for tumors larger than 3.5 cm, or when immediate tumor mass decompression is required.
  • Small tumors (ie, < 3.5 cm) that cause minimal edema and are surgically accessible may be treated with either surgery or SRS.
  • There is controversy over whether whole brain radiation therapy (WBRT) can be omitted following surgical resection or SRS.
  • Clinicians who choose to omit upfront WBRT are obligated to monitor the patient closely for intracranial recurrence, at which time further salvage therapy in the form of surgery, SRS, or WBRT may be considered.
  • Histology is of particular importance when considering WBRT for patients with radioresistant tumors such as melanoma, renal cell carcinoma, or sarcoma.
  • Chemotherapy has been demonstrated to improve response rates when used as an adjunct to radiation therapy.
  • Phase III trials to assess the benefit of motexafin in patients with metastatic lung cancer and efaproxiral in patients with metastatic breast cancer are ongoing.
  • Targeted therapies offer promise in achieving therapeutic efficacy while minimizing side effects.
  • [MeSH-major] Brain Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Neoplasm Metastasis. Radiosurgery. Salvage Therapy. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rev. 2005 Jun;31(4):256-73 [15951117.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2784-91 [16288488.001]
  • [Cites] J Neurooncol. 1998 Mar;37(1):1-8 [9525832.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2529-36 [12829672.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Dec;52(3):199-215 [15582786.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:147-50 [15662799.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):549-58 [10078636.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5 Suppl):S54-65; discusssion S1-4 [16237290.001]
  • [Cites] Neurosurgery. 1991 Feb;28(2):201-5 [1997887.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17 ):3644-50 [12202665.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Neurosurg. 1996 May;84(5):748-54 [8622147.001]
  • [Cites] Lancet Neurol. 2005 May;4(5):289-98 [15847842.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):53-7 [10582669.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):106-14 [16314619.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2700-9 [10561344.001]
  • [Cites] Lancet. 2004 May 22;363(9422):1665-72 [15158627.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2101-7 [15169796.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):519-26 [12062592.001]
  • [Cites] Oncology (Williston Park). 1999 Jul;13(7):941-54, 957-61; discussion 961-2, 9 [10442342.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Mar;5(3):419-25 [457486.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):27-35 [8641923.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3522-30 [10550150.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1042-7 [15205197.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1318-26; discussion 1326 [12762877.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8870-6 [16314647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):581-9 [9806518.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1295-304 [16525185.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3563-9 [9817276.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 4;87(1):34-40 [7666461.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5 Suppl):S66-77; discusssion S1-4 [16237291.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1169-76 [12654423.001]
  • [Cites] Expert Rev Neurother. 2004 Nov;4(6):1015-22 [15853528.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5514-20 [14654531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] J Neurosurg. 1993 Aug;79(2):210-6 [8331402.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):427-34 [10487566.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Dec;15(6):1085-107, vii [11770300.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1470-6 [8839553.001]
  • [Cites] Ann Neurol. 1993 Jun;33(6):583-90 [8498838.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5 Suppl):S24-32; discusssion S1-4 [16237284.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):129-38 [15603863.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Aug;128(8):417-25 [12200598.001]
  • [Cites] Am J Clin Oncol. 2005 Apr;28(2):173-9 [15803013.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1209-17 [15718318.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4):701-9; discussion 701-9 [16575334.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):183-90 [7707405.001]
  • (PMID = 17032560.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 58
  •  go-up   go-down


28. Langer CJ, Natale RB: The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin Oncol; 2005 Dec;32(6 Suppl 10):S23-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the United States, non-small cell lung cancer (NSCLC) constitutes 85% of all newly diagnosed lung cancers.
  • However, resection is feasible in less than 35% of patients at diagnosis, and 40% to 50% of newly diagnosed patients present with metastatic disease.
  • Platinum-based combination chemotherapy is standard treatment for these patients, but improvement beyond platinum doublets has not been achieved.
  • Therefore, a clear-cut need exists for new treatment approaches for NSCLC.
  • Targeted therapies, particularly angiogenesis inhibitors, are hoped to facilitate therapeutic progress.
  • A randomized phase III trial evaluated the role of the anti-VEGF-A antibody bevacizumab in combination with paclitaxel and carboplatin versus chemotherapy alone in NSCLC.
  • Based on toxicity observations from a phase II study, this trial excluded patients with squamous histology, brain metastases, or an ongoing need for therapeutic anti-coagulation or non-steroidal anti-inflammatory agents.
  • Preliminary data confirmed a survival advantage of 12.5 months for patients in the bevacizumab arm compared with 10.2 months in the control arm (P = .0075), which showed that antiangiogenic therapies can be effective in NSCLC.
  • Antiangiogenic therapies, including antibodies against VEGF, and, in particular, new small-molecule inhibitors of the VEGF receptor, are reviewed and discussed in detail.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Enzyme Inhibitors / therapeutic use. Lung Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Angiogenesis Inhibitors. Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Neovascularization, Pathologic. Prognosis. Randomized Controlled Trials as Topic. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / physiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459176.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 63
  •  go-up   go-down


29. Sarkar S, Kundu AK, Chakrabarti S: Lungs: victim of synchronous double malignancies. J Assoc Physicians India; 2007 Mar;55:235-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 20 year young man was referred to our institution with superior vena cava (SVC) syndrome, multiple lung opacities and a mass lesion in the right upper zone (RUZ).
  • CT-guided FNAC from the mass lesion was consistent with the diagnosis of non-small cell lung carcinoma (NSCLC).
  • Both FNAC and excisional biopsy of the testicular mass confirmed the diagnosis of immature teratoma with choriocarcinoma, a form of non-seminomatous germ cell tumour (NSGCT).
  • With chemotherapy all metastatic lesions of lung and SVC syndrome disappeared, and the tumour-marker levels decreased.
  • However, the opacity in RUZ progessed to involve right recurrent laryngeal nerve at thoracic inlet, metastasized to the brain, and the patient expired after 4th cycle of chemotherapy.
  • [MeSH-major] Choriocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Humans. Male. Paraneoplastic Syndromes / etiology. Superior Vena Cava Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598338.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


30. Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M: [Complete resection of urothelial cancer metastases with curative intent]. Urologe A; 2009 Feb;48(2):143-50
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent publications suggest that a subgroup of patients can benefit from surgical removal of transitional cell carcinoma (TCC) metastases in addition to systemic chemotherapy.
  • MATERIALS AND METHODS: Forty-four patients with distant metastatic TCC of the bladder or upper urinary tract underwent resection of all detectable metastases in 15 different German uro-oncological centers between 1991 and 2008 in an attempt to be rendered free of disease.
  • RESULTS: The resected metastatic sites consisted of retroperitoneal lymph nodes (56.8%), distant lymph nodes (11.3%), lung (18.2%), bone (4.5%), adrenal gland (2.3%), brain (2.3%), small intestine (2.3%), and skin (2.3%).
  • The treatment sequence included systemic chemotherapy in 35/44 (79.5%) patients before and/or after surgery.
  • Median survival times from initial diagnosis of metastatic TCC and subsequent resection were as follows: overall survival, 35 and 27 months, respectively; cancer-specific survival, 38 and 34 months, respectively; and progression-free survival, 19 and 15 months, respectively.
  • Seventeen patients were still alive without progression at a median follow-up time of 8 months.
  • However, prospective data to identify patients most likely to benefit from this aggressive therapeutic approach are lacking.
  • Therefore, metastasectomy in patients with disseminated TCC remains investigational and should be offered only to those with limited disease as a combined-modality approach with systemic chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Humans. Lymphatic Metastasis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2003 Jun;169(6):2113-7 [12771730.001]
  • [Cites] J Urol. 1994 Mar;151(3):598-600; discussion 600-1 [8308966.001]
  • [Cites] J Urol. 2001 Mar;165(3):811-4 [11176475.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2546-52 [10561321.001]
  • [Cites] J Urol. 2006 Jul;176(1):53-7; discussion 57 [16753366.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1361-7 [11870180.001]
  • [Cites] Eur Urol. 2007 Oct;52(4):1106-13 [17367917.001]
  • [Cites] Curr Opin Urol. 2004 Sep;14(5):287-93 [15300149.001]
  • [Cites] J Urol. 1993 Jul;150(1):65-9 [8510277.001]
  • [Cites] Eur Urol. 2002 Feb;41(2):105-12 [12074395.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] J Urol. 2004 Jan;171(1):145-8 [14665863.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):1050-5 [2189954.001]
  • [Cites] J Urol. 2002 Mar;167(3):1295-8 [11832716.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):483-8 [7509853.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2638-46 [11352955.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] Eur Urol. 2009 Jun;55(6):1293-9 [19058907.001]
  • [Cites] Urology. 2001 Jan;57(1):55-9 [11164143.001]
  • [Cites] J Urol. 1988 Mar;139(3):461-9 [3343727.001]
  • [Cites] Urology. 1982 Oct;20(4):390-2 [7147508.001]
  • (PMID = 19142626.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


31. Aguiar D, Pazo R, Durán I, Terrasa J, Arrivi A, Manzano H, Martín J, Rifá J: Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol; 2004 Feb;66(3):345-50
Hazardous Substances Data Bank. PHENYTOIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many patients with primary or metastatic intracranial tumours receive anticonvulsants for seizure prophylaxis despite their efficacy not having been clearly demonstrated.
  • Moreover, several cases have been reported in the literature in which serious adverse drug reactions such as TEN and Stevens-Johnson syndrome (SJS) have occurred following anticonvulsants exposure.
  • In some of these cases the effect of radiation therapy and the tapering of steroid dose on the pathogenesis of these reactions have been highlighted.
  • We report, here, a case of TEN that appeared in a patient receiving phenytoin, and shortly after the end of cranial and thoracic irradiation therapy for brain metastases of non-small cell lung cancer.
  • Clinical considerations about diagnosis of SJS and TEN are presented.
  • [MeSH-minor] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / therapy. Humans. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Sep;55(9):753-7 [1402964.001]
  • [Cites] N Engl J Med. 1992 Sep 10;327(11):765-71 [1298221.001]
  • [Cites] J Neurosurg. 1983 May;58(5):672-7 [6339686.001]
  • [Cites] Pharmacotherapy. 1999 Feb;19(2):223-7 [10030773.001]
  • [Cites] Arch Dermatol. 1987 Sep;123(9):1160-5 [3632000.001]
  • [Cites] Epilepsia. 1999 Mar;40(3):341-4 [10080516.001]
  • [Cites] Epilepsia. 2002 Feb;43(2):175-82 [11903465.001]
  • [Cites] Lancet. 1999 Jun 26;353(9171):2190-4 [10392983.001]
  • [Cites] J Am Acad Dermatol. 1999 Mar;40(3):458-61 [10071318.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] Br J Dermatol. 1994 Oct;131(4):586-7 [7947221.001]
  • [Cites] Eur J Dermatol. 2002 Sep-Oct;12(5):503-5 [12370147.001]
  • [Cites] Arch Dermatol. 1993 Jan;129(1):92-6 [8420497.001]
  • [Cites] Neurology. 1996 Apr;46(4):985-91 [8780077.001]
  • [Cites] Am J Clin Oncol. 2001 Aug;24(4):347-50 [11474258.001]
  • [Cites] N Engl J Med. 1995 Dec 14;333(24):1600-7 [7477195.001]
  • [Cites] Int J Dermatol. 1989 Sep;28(7):441-4 [2777442.001]
  • [Cites] Int J Dermatol. 1991 Oct;30(10):747-9 [1955236.001]
  • [Cites] Acta Oncol. 1999;38(1):111-6 [10090698.001]
  • [Cites] Lancet. 1985 Jul 6;2(8445):45 [2861495.001]
  • [Cites] Acta Neurochir (Wien). 1990;103(1-2):47-51 [2360466.001]
  • [Cites] Epilepsia. 1998;39 Suppl 7:S3-7 [9798755.001]
  • [Cites] Seizure. 1996 Dec;5(4):291-8 [8952015.001]
  • [Cites] J Neurooncol. 1983;1(4):313-7 [6678974.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1621-4 [3171627.001]
  • [Cites] J Am Acad Dermatol. 1989 Aug;21(2 Pt 1):317-22 [2671067.001]
  • [Cites] J Cutan Med Surg. 2001 Nov-Dec;5(6):475-8 [11907855.001]
  • [Cites] Epilepsia. 1999 Jul;40(7):985-91 [10403224.001]
  • [Cites] J Am Acad Dermatol. 1991 Nov;25(5 Pt 1):778-86 [1802900.001]
  • [Cites] Neurology. 1997 Aug;49(2):542-6 [9270593.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 2):898-9 [11044815.001]
  • [Cites] Neurology. 1988 Feb;38(2):194-8 [3340279.001]
  • [Cites] Australas Radiol. 1995 Feb;39(1):42-6 [7695527.001]
  • [Cites] Am J Clin Oncol. 1996 Feb;19(1):32-4 [8554032.001]
  • [Cites] Br J Dermatol. 1956 Nov;68(11):355-61 [13374196.001]
  • [Cites] Eur J Cancer. 1993;29A(3):478-9 [8398354.001]
  • [Cites] Can J Neurol Sci. 2003 May;30(2):106-12 [12774949.001]
  • [Cites] Neurology. 1990 Jul;40(7):1144-5 [2356019.001]
  • [Cites] J Am Acad Dermatol. 1999 Mar;40(3):493-6 [10071329.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):299-307 [11981275.001]
  • (PMID = 15015667.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 6158TKW0C5 / Phenytoin
  •  go-up   go-down






Advertisement